Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: July 2010

Home/2010/July
13 07, 2010

More About When To Get A Stem Cell Transplant (SCT) & Success Of RVD Drug Combo

Tags: , , , , , , , , , |0 Comments

Here is the body of the article about multiple myeloma related research studies I started to post yesterday,  Is It Time to Abandon Up-Front Transplantation in Multiple Myeloma? Elsevier Global Medical News, written by P. Wendling on the medical professionals only site, Oncology STAT: He (Dr. Jean-Luc Harousseau) cited data from several trials, including the pivotal phase

12 07, 2010

CancerCare Online Educational Workshop: Advances In The Treatment Of Multiple Myeloma Scheduled For August

Tags: , |0 Comments

A reader, Marti, forwarded information to me today about  an upcoming Connect Education Workshop:  Advances in the Treatment of Multiple MyelomaThe Workshop will take place on Wednesday, August 11, 2010, 1:30 – 2:30 pm ETSpeakersKenneth C. Anderson, MDKraft Family Professor of Medicine, Harvard Medical School, Chief, Division of Hematologic Neoplasia, Director, LeBow Institute for Myeloma Therapeutics,

11 07, 2010

European Hematology Association Finds Donor Stem Cell Transplants Are Not More Effective Than Existing Treatments For Multiple Myeloma

Tags: , , , , , , |0 Comments

Friday I wrote about my four part series featured on/in The Myeloma Beacon.  The Beacon is an excellent, independent source for multiple myeloma related news.  Here is an example:Donor Stem Cell Transplant Is Not More Effective Than Existing Treatments For Multiple Myeloma (EHA 2010) by Melissa Cobleigh, July 9, 2010 The results of a recent

10 07, 2010

INK 128: Another Example Of An Anti-Cancer Compound Which Shows Potential Against Multiple Myeloma

Tags: , , |1 Comment

Yesterday I wrote about perifisone.  This exciting new anti-cancer compound is being tested on several types of cancer in addition to multiple myeloma.  Here is another example of a new crossover cancer drug.  INK128 is a novel, orally available small molecule inhibitor of the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway,

9 07, 2010

Anti-Myeloma Drug, Perifosine, May Also Work Against Colon Cancer

Tags: , , , , , |0 Comments

Interesting news I wanted to share about one of several new anti-myeloma therapy agents, perifosine.  Currently in Phase 3 trials in combination with Velcade, perifosine apparently has anti-cancer properties which go far beyond multiple myeloma:  Aeterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Trial with Perifosine in Colorectal CancerThe

8 07, 2010

Young Women With Multiple Myeloma at Highest Risk for Nausea and Pain From Stem Cell Transplant

Tags: , |3 Comments

I first wrote about this surprising trend in March.  At the time, I did not realize woman are at higher risk for pain and nausea following a stem cell transplant:  March 16, 2010 (Atlanta, Georgia) — Researchers have identified predictors of adverse symptoms in cancer patients undergoing hematopoietic stem cell transplantation (HSCT) and found that being

7 07, 2010

Multiple Myeloma Related Political Update

Tags: , |0 Comments

As much as many of us would like to avoid politics or ignore political realities, that may not be wise.  Cancer research funding (including multiple myeloma) is often tied to otherwise unrelated pieces of state and federal legistlation.  Here is an update from The International Myeloma Foundations's (IMF)Advocacy Assistant Meghan Buzby:Long Stalled Appropriations Process Begins

5 07, 2010

How/Why Does Revlimid Work?

Tags: , , , , , |1 Comment

I have now been using Revlimid (lenalidomide) for 35 consecutive months and it is still working! But how does it work? Lenalidomide is an immune-modulating therapy that acts to improve the immune system. Administered orally, lenalidomide also helps block the blood supply to cancer cells so that tumors cannot grow. Lenalidomide is molecular variation, or analogue,

2 07, 2010

Battle Of The New Multiple Myeloma Novel Therapy Agents: Why I Expect Carfilzomib To Gain FDA Fast Track Approval Sooner Than Pomalidomide

Tags: , , , , , , |0 Comments

One of our readers recently sent me the following e-mail: Hey Pat, Great job down at ASCO. I have a question: while you were down there, did you get a sense about when Celgene might push for pomalidomide's approval? Thanks. Feel good. -- Gregg I responded this way: Hi Gregg- Pomalidomide seemed a bit "under

1 07, 2010

Panobinostat/Velcade Combination Helps 62% Of Patients Refractory To Velcade Alone

Tags: , , |0 Comments

Here is a study I didn't write much about from ASCO last month..  Presented by Dr. Jóse San Miguel of Hospital Universitario de Salamanca, Spain, the study revealed data examining VELCADE in combination with the novel agent panobinostat. The open-label, multi-center, dose-escalation study presented the following results for 38 evaluable patients:• Responses were observed in 68%